Nature

Systematic discovery of improved CAR T cell cancer therapies boosted by gene editing

Updated

Abstract

Essence

A screening platform identified gene edits, especially RHOG knockout alone or with FAS knockout, that improved CAR T cell performance in preclinical models.

Evidence

This preclinical platform study combined genome-wide, combinatorial, and base-editing CRISPR screens in human primary CAR T cells with in vivo xenograft leukemia validation across multiple CAR designs, donors, and patient-derived cells.

Caveat

The evidence comes from engineered human cells and xenograft models rather than clinical trials in patients.

Simplified

Key numbers

Increase in T cell abundance
Measured increase in CD4 in spleen after RHOG .
10×
Increase in CD8
Measured increase in CD8 in bone marrow after RHOG .
25%
Percentage of with
Percentage of positive for , and TIGIT after treatment.

Key figures

Fig. 1
Genome-wide fitness screens in human primary under and stimulation
Frames a clear contrast in gene fitness effects between TCR and CAR stimulation highlighting targets that enhance CAR T cell function
41586_2025_9507_Fig1_HTML
  • Panel a
    Schematic overview of the platform workflow including T cell isolation, activation, lentiviral transduction with CAR and library, CRISPR mRNA , selection, functional screening, and combinatorial screens
  • Panel b
    Experimental timeline showing T cell isolation, activation, transduction, electroporation, antibiotic selection, and repeated stimulation with anti-CD3/CD28 (TCR) or CD19 K562 cells (CAR), with genomic DNA collected at days 0, 7, 14, and 21
  • Panel c
    Schematic of TCR and CAR signaling pathways with gene-level log fold changes (day 14 vs day 0) from fitness screens mapped onto proteins; top half colors represent TCR stimulation results, bottom half represent CAR stimulation
  • Panel d
    Scatter plot of gene effect sizes comparing TCR versus CAR stimulation screens; green dots indicate genes with increased fitness, magenta are known negative regulators, purple are essential genes, and blue are neutral olfactory receptors
Fig. 2
Genome-wide screens identifying gene affecting T cell surface markers and functions
Highlights gene knockouts that visibly enhance CAR T cell activation and reduce exhaustion, spotlighting targets for improved immunotherapy.
41586_2025_9507_Fig2_HTML
  • Panel a
    Diagram of CAR T cell surface proteins used as screening markers: CD19 (target recognition), (activation), (apoptosis), and (exhaustion).
  • Panel b
    Scatterplots showing gene knockout enrichment in marker-negative for CD69, FAS, and PD-1/LAG3/TIM3; significant genes are colored and marker genes labeled.
  • Panel c
    Scatterplots showing gene knockout enrichment in marker-positive CAR T cells for CD19 trogocytosis, CD69 activation, FAS apoptosis, and PD-1/LAG3/TIM3 exhaustion; significant genes are colored and labeled.
  • Panel d
    Bubble plot summarizing top gene knockouts improving CAR T cell properties across genome-wide fitness (blue) and -based screens (green), with validated immunotherapy targets highlighted in magenta.
Fig. 3
In vivo screening of T cell gene in leukaemic mice
Highlights stronger clonal expansion and higher gene knockout representation in at day 21 in spleen versus bone marrow
41586_2025_9507_Fig3_HTML
  • Panel a
    Experimental timeline showing injection of NALM6 leukaemia cells and CAR T cells, with organ collection at days 9 and 21 for analysis
  • Panel b
    Vector design and workflow of in vivo CROP-seq method detecting gRNA and from CAR T cell transcripts using PCR and paired-end sequencing
  • Panel c
    Comparison of gRNA detection efficiency using genomic DNA versus mRNA/cDNA with standard and nested PCR, showing higher detection from mRNA with nested PCR
  • Panel d
    Volcano plots of gRNA enrichment or depletion in bone marrow and spleen at days 9 and 21, highlighting significant gene knockouts including RHOG, , PRDM1, and CDKN2A
  • Panel e
    Knee plots ranking CAR T cell clones by read counts in bone marrow, spleen, and background, separating distinct clones from noise
  • Panel f
    Bar graph showing number of distinct CAR T cell clones detected in bone marrow and spleen for two donors at days 9 and 21, with more clones at day 21
  • Panel g
    Stacked bar plots of gRNA read percentages before injection and at days 9 and 21 in bone marrow and spleen, showing dominance of top gene knockouts (RHOG, FAS, PRDM1) by day 21
Fig. 4
Standard vs RHOG, , and double- : leukemia control, survival, and T cell characteristics in mice
Highlights improved leukemia control and survival with RHOG knockout CAR T cells alongside increased memory and proliferation features.
41586_2025_9507_Fig4_HTML
  • Panel a
    Experimental timeline showing leukemia induction in mice and treatment with standard or knockout CAR T cells.
  • Panels b and c
    Tumor load over time measured by for two donors; knockout and double-knockout CAR T cells show reduced tumor load compared to standard CAR T cells.
  • Panel d
    Survival curves for mice treated with untreated, standard, FAS knockout, RHOG knockout, or double-knockout CAR T cells; RHOG and double-knockout groups show higher survival probability.
  • Panel e
    Survival analysis combining all mice treated with RHOG knockout versus standard CAR T cells; RHOG knockout group shows significantly improved survival.
  • Panel f
    Percentage of central memory T cells (CD45RO+CD62L+) among knockout or standard CAR T cells after repeated stimulation; knockout cells show higher central memory percentages.
  • Panel g
    Fold increase in CD4+ and CD8+ T cell numbers in mice treated with knockout or standard CAR T cells on day 15; knockout group shows higher fold increase.
  • Panel h
    Percentage of knockout CAR T cells positive for , and TIGIT on day 15; no significant differences observed.
  • Panel i
    Conceptual summary illustrating DNA replication, proliferation, memory phenotype, and exhaustion differences between standard and RHOG-knockout CAR T cells.
Fig. 5
Combinatorial gene editing effects on T cell fitness and RHOG mutagenesis using screening.
Highlights combinatorial gene editing effects and specific RHOG mutations that influence CAR T cell fitness and function.
41586_2025_9507_Fig5_HTML
  • Panel a
    Experimental timeline for combinatorial fitness screens with four donors, three CAR designs, and 238 combinations.
  • Panel b
    Vector design showing dual-gRNA cassette with three different CAR constructs driven by a CMV promoter.
  • Panel c
    Ranking of fitness effects for pairwise gene comparing day 12 versus day 0, with symbols indicating CAR antigen and signaling domains.
  • Panel d
    Overview of saturation screening library including all possible gRNAs tiling RHOG, puromycin resistance gene, essential genes, and .
  • Panel e
    Number and type of base-editing mutations introduced by four CRISPR base editors, categorized by mutation type and dependency.
  • Panel f
    Mutagenesis map of RHOG showing log fold change of gRNAs introducing missense or nonsense mutations after CAR restimulation, with top 15 enriched gRNAs labeled.
  • Panel g
    Structural mapping of amino acids with strongest mutagenesis effects on RHOG protein, focusing on the GTP-binding site.
1 / 5

Full Text

What this is

  • CAR T cell therapy is a promising treatment for blood cancers, but its effectiveness is often limited by various biological factors.
  • This research introduces , a screening platform designed to enhance CAR T cell performance by targeting specific genes.
  • Through genome-wide screens in human primary CAR T cells, the study identifies gene knockouts that improve T cell efficacy, particularly focusing on the RHOG gene.

Essence

  • enables the identification of -boosted CAR T cells that outperform standard CAR T cells, particularly through the knockout of the RHOG gene, which enhances T cell proliferation and reduces exhaustion.

Key takeaways

  • allows for high-content screening in primary CAR T cells, addressing challenges like efficient co-delivery and relevant readouts.
  • Knockout of RHOG significantly enhances CAR T cell efficacy, leading to improved proliferation and reduced exhaustion, demonstrating its potential as a therapeutic target.
  • The study validates multiple gene knockouts across various CAR designs and patient-derived cells, establishing a foundational resource for optimizing CAR T cell therapies.

Caveats

  • The study primarily focuses on in vitro and preclinical models, which may not fully predict clinical outcomes in human patients.
  • While the findings are promising, further validation in larger clinical trials is necessary to confirm the safety and efficacy of the identified gene knockouts.

Definitions

  • CELLFIE: A CRISPR screening platform for optimizing CAR T cells by identifying gene knockouts that enhance their therapeutic efficacy.
  • CRISPR: A genome-editing technology that allows for precise modifications of DNA in living organisms.

Simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free